search
Back to results

To Evaluate the Safety and Efficacy of TQB2858 Injection to the Subjects With Recurrent/Metastatic Nasopharyngeal Cancer

Primary Purpose

Recurrent / Metastatic Nasopharyngeal Cancer

Status
Recruiting
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
TQB2858 Injection
Anlotinib Hydrochloride Capsule
Gemcitabine hydrochloride injection
Cisplatin Injection
Sponsored by
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Recurrent / Metastatic Nasopharyngeal Cancer

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • 1 Voluntarily joined the study and provide written informed consent and authorization permitting release of Protected Health Information.
  • 2 Male or female patient ≥18 and ≤75 years of age, an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1, and life expectancy ≥12 weeks.
  • 3 Histologically or cytologically proven diagnosis of nasopharyngeal cancer (NPC), Stage IVb or not amenable for or local treatment (based on 2017, the 8th edition of the American Joint Committee on Cancer (AJCC) staging system of tumor-node-metastasis (TNM) of nasopharyngeal cancer).
  • 4 Subject meets one of the following criteria:

    • Arm 1: Progression (Tumor-imaging proven) after platinum-based chemotherapy and Tumor Immunotherapy (PD-1/PD-L1 Checkpoint Inhibitors, etc.).
    • Attention: Progression during therapy or after therapy within 6 months, neoadjuvant/ adjuvant therapy, radical chemoradiotherapy are considered as the first-line treatment.
    • Arm 2 and 3: Not received systemic anti-tumor therapy for recurrent / metastatic nasopharyngeal cancer.
    • Attention: Progression after therapy more than 6 months, neoadjuvant/ adjuvant therapy, radical chemoradiotherapy are not considered as the first-line treatment.
  • 5 Have at least 1 measurable disease defined by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1).
  • 6 Have adequate baseline function and performance status:

    • a) Standard hematology test (no blood or product transfusions for a period of at least 7 days prior to enrollment).

      i. Hemoglobin (HGB) >90 g/L; ii. Neutrophil count (NEUT) ≥1.5 × 109/L; iii. Platelets (PLT) ≥75 × 109/L;

    • b) Serum chemistry i. Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) ≤ 2.5 upper limit of normal (ULN) or ≤ 5 x ULN for subjects with hepatic metastatic tumor; ii. Bilirubin ≤ 1.5 x ULN or ≤ 3.0 x ULN for subjects with Gilbert Syndrome; iii. Creatinine ≤ 1.5 x ULN or Creatinine Clearance ≥ 60 mL/min;
    • c) Blood Coagulation Test i. Activated Partial Thromboplastin Time (APTT), International Normalized Ratio (INR) and Prothrombin Time (PT) ≤ 1.5 (No anticoagulant therapy);
    • d) left ventricular ejection fraction (LVEF) ≥ 50%;
  • 7 Women of child-bearing potential must agree to use contraceptive method(s) throughout the study and for at least 180 days after the last dose of assigned treatment. Serum pregnancy test negative within 7 days before enrollment and must be non-lactating.

Exclusion Criteria:

  • 1 Complicated disease and history:

    1. Has developed other malignant tumors within 3 years or is currently suffering from;
    2. With factors affecting take medicine orally (such as unable to swallow drugs or bowel obstruction, etc.)
    3. Unmitigated toxic reactions above Common Terminology Criteria for Adverse Events (CTCAE) grade 1 due to any prior treatment, excluding hair loss and peripheral sensory nerve disorders related to platinum-based chemotherapy;
    4. Received major surgical treatment, significant traumatic injury or long-term unhealed wounds or fractures (excluding needle biopsy for diagnosis, endoscope, etc.) within 28 days prior to the commencement of study treatment;
    5. With arterial/venous thrombotic events within 6 months, such as cerebrovascular accidents (including temporary ischemic attack, cerebral hemorrhage), deep venous thrombosis and pulmonary embolism;
    6. With active pulmonary tuberculosis, idiopathic pulmonary fibrosis, organized pneumonia, drug-induced pneumonia, radiation pneumonia requiring treatment or active pneumonia with clinical symptoms;
    7. History of psychotropic substance abuse and inability to quit or with mental disorders;
    8. Received allogeneic bone marrow transplantation or solid organ transplantation;
    9. Subjects with any severe and/or uncontrolled disease:

      • i. Uncontrolled hypertension (defined as systolic BP >150 mm Hg or diastolic BP > 100 mm Hg pressure)
      • ii. Grade 2 or greater cardiac ischemia, myocardial infarction or cardiac arrhythmia (including QTc ≥ 480 ms) ;and New York Heart Association (NYHA) Grade II or greater congestive heart failure;
      • iii. Active or uncontrolled infections;
      • iv. Decompensated liver cirrhosis and active hepatitis (Hepatitis B reference: HBsAg positive, and HBV DNA> 2500 copy/mL or > 500 IU/mL; Hepatitis C reference: HCV antibody positive, and HCV RNA > ULN);
      • v. Renal failure requiring hemodialysis or peritoneal dialysis;
      • vi. Known history of immunodeficiency infection;
      • vii. Urinalysis:urine protein ≥ ++,and confirmed 24-hour urinary protein > 1.0g;
  • 2 Tumor-related symptoms and treatment:

    1. History of surgery, chemotherapy, radiation or other anti-tumor therapy within 4 weeks prior to enrollment (calculated from the date of the last dose);
    2. History of Chinese patent drugs with anti-tumor indications approved by National Medical Products Administration (NMPA) (including compound cantharide capsule, Kangai injection, Kanglaite capsule/injection, Aidi injection, Brucea oil injection/capsule, Xiaoaoping tablet/injection, Huabenin capsule, etc.) within 2 weeks before enrollment;
    3. History of Tumor Immunotherapy of TGF-β inhibition;
    4. Previously received bevacizumab, arotinib, apatinib, renvatinib or other anti-vascular targeted drug therapy;
    5. History of secondary radiotherapy;
    6. Imaging (CT or MRI) evidence of tumor invading the significant blood vessels or likely to invade and cause fatal massive bleeding during study, accessed by investigators;
    7. With uncontrolled pleural effusion, pericardial effusion, or ascites that requires repeated drainage;
    8. Known uncontrolled or symptomatic active central nervous system (CNS) metastasis (characterized by clinical symptoms, brain edema, spinal cord compression, cancerous meningitis, leptomeningeal disease and /or progressive growth); (exclude those, with the history of CNS metastasis or spinal cord compression, clinical symptoms stabilized less than 4 weeks after discontinuation of dehydrants and steroids);
  • 2 Research Treatment Related:

    1. History of live attenuated vaccine vaccination within 28 days prior to enrollment or planing of live attenuated vaccine vaccination during the study period;
    2. Definite bleeding tendency or bleeding symptoms with significant clinical significance within 28 days prior enrollment, including gastrointestinal bleeding, nasal bleeding (excluding epistaxis and retractive runny nose), and with hemorrhagic diseases or coagulation disorders;
    3. History of hemoptysis or hemoptysis within 28 days prior enrollment (defined as coughing or coughing out ≥ 1 teaspoon of blood or small blood clots or only coughing up blood without sputum) , blood in sputum are not excluded;
    4. Severe allergy history of antibody drugs or others;
    5. History of active autoimmune disease requiring systemic treatment within 2 years prior to enrollment (e.g. palliative drugs, corticosteroids, or immunosuppressants) .

      • i. Including autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hypophysitis, vasculitis, nephritis, hyperthyroidism or multiple sclerosis;
      • ii. Exclude Skin diseases without systemic treatment, such as vitiligo, psoriasis and hair loss;
      • iii. Including asthma requiring medical intervention with bronchodilators;
      • iv.Alternative therapy (such as thyroxine, insulin, or physiological corticosteroids for adrenal or pituitary insufficiency) is not considered as systemic therapy;
    6. Diagnosed with immunodeficiency or receiving systemic glucocorticoid therapy or any other form of immunosuppressive therapy. (dose of >10mg/ day prednisone or other equivalent efficacy hormone), and continued to use within 2 weeks prior to enrollment;
  • 4 History of participating in other anti-tumor clinical trials in the previous 4 weeks;
  • 5 Other damage to the safety of patients or other situations affecting patients to complete the study, assessed by investigators.

Sites / Locations

  • Affiliated Cancer Hospital and Institute of Guangzhou Medical UniversityRecruiting
  • Sun-Yat-Sen University Cancer CenterRecruiting
  • Peking University Shenzhen HospitalRecruiting
  • The Fifth Affiliated Hospital Sun Yat-Sen UniversityRecruiting
  • Guangxi Tumor HospitalRecruiting
  • Hainan General HospitalRecruiting
  • Hunan Cancer HospitalRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

TQB2858 Injection combining with other drugs

Arm Description

Combination 1 is TQB2858 Injection and Anlotinib Hydrochloride Capsules. Combination 2 is TQB2858 Injection, Gemcitabine Hydrochloride Injection and Cisplatin Injection for 4-6 cycles of induction chemotherapy, then using TQB2858 Injection and Anlotinib Hydrochloride Capsules for maintenance treatment. Combination 3 is TQB2858 Injection, Gemcitabine Hydrochloride Injection, Cisplatin Injection and Anlotinib Hydrochloride Capsules for 4-6 cycles of induction chemotherapy, then using TQB2858 Injection and Anlotinib Hydrochloride Capsules for maintenance treatment.

Outcomes

Primary Outcome Measures

Adverse event rate
The occurrence of all adverse events (AEs), serious adverse events (SAEs) and treatment-related adverse events (TEAEs).

Secondary Outcome Measures

Objective Response Rate(ORR)
The percentage of participants with a best overall response defined as complete response (CR) or partial response (PR).
Progression-free survival (PFS)
The time from enrollment to the date of the first documentation of objective progression of disease or death due to any cause, whichever occurs first.
Disease Control rate (DCR)
Calculated as the percentage of participants with best overall response of CR, PR, stable disease (SD) and Non-CR/Non-progressive disease (PD).
Duration of Overall Response (DOR)
The time from the date of participants with a first overall response defined as complete response (CR) or partial response (PR) to the date of the first documentation of objective progression of disease or death due to any cause, whichever occurs first.
Overall survival (OS)
The time from enrollment to the time of death from any cause.

Full Information

First Posted
January 19, 2022
Last Updated
January 19, 2022
Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT05198531
Brief Title
To Evaluate the Safety and Efficacy of TQB2858 Injection to the Subjects With Recurrent/Metastatic Nasopharyngeal Cancer
Official Title
Phase Ib Clinical Study to Evaluate the Safety and Efficacy of TQB2858 Injection to the Subjects With Recurrent/Metastatic Nasopharyngeal Cancer
Study Type
Interventional

2. Study Status

Record Verification Date
January 2022
Overall Recruitment Status
Recruiting
Study Start Date
January 2022 (Anticipated)
Primary Completion Date
October 2022 (Anticipated)
Study Completion Date
August 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
This study is a single-arm, randomized, open-label, multi-cohort Phase Ib clinical trial. The experimental drug is TQB2858 Injection. The trial was divided into 3 cohorts. Cohort 1 included patients with advanced nasopharyngeal carcinoma who had previously failed platinum-based chemotherapy and immune checkpoint inhibitors (programmed cell death protein 1 (PD-1)/ Programmed death-ligand 1 (PD-L1), etc.). Cohorts 2 and 3 were randomized into patients with advanced, untreated nasopharyngeal carcinoma who had not received prior systemic therapy. A total of 60-90 subjects are required.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Recurrent / Metastatic Nasopharyngeal Cancer

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
90 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
TQB2858 Injection combining with other drugs
Arm Type
Experimental
Arm Description
Combination 1 is TQB2858 Injection and Anlotinib Hydrochloride Capsules. Combination 2 is TQB2858 Injection, Gemcitabine Hydrochloride Injection and Cisplatin Injection for 4-6 cycles of induction chemotherapy, then using TQB2858 Injection and Anlotinib Hydrochloride Capsules for maintenance treatment. Combination 3 is TQB2858 Injection, Gemcitabine Hydrochloride Injection, Cisplatin Injection and Anlotinib Hydrochloride Capsules for 4-6 cycles of induction chemotherapy, then using TQB2858 Injection and Anlotinib Hydrochloride Capsules for maintenance treatment.
Intervention Type
Drug
Intervention Name(s)
TQB2858 Injection
Intervention Description
TQB2858 Injection, a bifunctional fusion protein against Programmed death ligand 1 (PD-LI) and transforming growth factor-β (TGF-β). TQB2858 Injection blocks the PD-1/PD-L1 pathway and neutralizes TGF-β in the tumor microenvironment.
Intervention Type
Drug
Intervention Name(s)
Anlotinib Hydrochloride Capsule
Intervention Description
Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor.
Intervention Type
Drug
Intervention Name(s)
Gemcitabine hydrochloride injection
Intervention Description
Gemcitabine hydrochloride, cell cycle-specific antimetabolites, mainly acting on tumor cells in the DNA synthesis phase (S phase cell). Under certain conditions, it can prevent the progression from G1 phase to S phase.
Intervention Type
Drug
Intervention Name(s)
Cisplatin Injection
Intervention Description
After cisplatin enters cells, it reacts with DNA to form cross-links between two points or two strands in DNA, thereby inhibiting DNA replication and transcription, resulting in DNA breaks and miscoding.
Primary Outcome Measure Information:
Title
Adverse event rate
Description
The occurrence of all adverse events (AEs), serious adverse events (SAEs) and treatment-related adverse events (TEAEs).
Time Frame
Baseline up to PD/die, about 20 months
Secondary Outcome Measure Information:
Title
Objective Response Rate(ORR)
Description
The percentage of participants with a best overall response defined as complete response (CR) or partial response (PR).
Time Frame
Baseline to CR/PR, about 16 months
Title
Progression-free survival (PFS)
Description
The time from enrollment to the date of the first documentation of objective progression of disease or death due to any cause, whichever occurs first.
Time Frame
Baseline to PD/die, about 20 months
Title
Disease Control rate (DCR)
Description
Calculated as the percentage of participants with best overall response of CR, PR, stable disease (SD) and Non-CR/Non-progressive disease (PD).
Time Frame
Baseline to CR/PR/SD, about 16 months
Title
Duration of Overall Response (DOR)
Description
The time from the date of participants with a first overall response defined as complete response (CR) or partial response (PR) to the date of the first documentation of objective progression of disease or death due to any cause, whichever occurs first.
Time Frame
Baseline up to PD/die, about 20 months
Title
Overall survival (OS)
Description
The time from enrollment to the time of death from any cause.
Time Frame
Baseline up to die, about 46 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 1 Voluntarily joined the study and provide written informed consent and authorization permitting release of Protected Health Information. 2 Male or female patient ≥18 and ≤75 years of age, an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1, and life expectancy ≥12 weeks. 3 Histologically or cytologically proven diagnosis of nasopharyngeal cancer (NPC), Stage IVb or not amenable for or local treatment (based on 2017, the 8th edition of the American Joint Committee on Cancer (AJCC) staging system of tumor-node-metastasis (TNM) of nasopharyngeal cancer). 4 Subject meets one of the following criteria: Arm 1: Progression (Tumor-imaging proven) after platinum-based chemotherapy and Tumor Immunotherapy (PD-1/PD-L1 Checkpoint Inhibitors, etc.). Attention: Progression during therapy or after therapy within 6 months, neoadjuvant/ adjuvant therapy, radical chemoradiotherapy are considered as the first-line treatment. Arm 2 and 3: Not received systemic anti-tumor therapy for recurrent / metastatic nasopharyngeal cancer. Attention: Progression after therapy more than 6 months, neoadjuvant/ adjuvant therapy, radical chemoradiotherapy are not considered as the first-line treatment. 5 Have at least 1 measurable disease defined by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1). 6 Have adequate baseline function and performance status: a) Standard hematology test (no blood or product transfusions for a period of at least 7 days prior to enrollment). i. Hemoglobin (HGB) >90 g/L; ii. Neutrophil count (NEUT) ≥1.5 × 109/L; iii. Platelets (PLT) ≥75 × 109/L; b) Serum chemistry i. Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) ≤ 2.5 upper limit of normal (ULN) or ≤ 5 x ULN for subjects with hepatic metastatic tumor; ii. Bilirubin ≤ 1.5 x ULN or ≤ 3.0 x ULN for subjects with Gilbert Syndrome; iii. Creatinine ≤ 1.5 x ULN or Creatinine Clearance ≥ 60 mL/min; c) Blood Coagulation Test i. Activated Partial Thromboplastin Time (APTT), International Normalized Ratio (INR) and Prothrombin Time (PT) ≤ 1.5 (No anticoagulant therapy); d) left ventricular ejection fraction (LVEF) ≥ 50%; 7 Women of child-bearing potential must agree to use contraceptive method(s) throughout the study and for at least 180 days after the last dose of assigned treatment. Serum pregnancy test negative within 7 days before enrollment and must be non-lactating. Exclusion Criteria: 1 Complicated disease and history: Has developed other malignant tumors within 3 years or is currently suffering from; With factors affecting take medicine orally (such as unable to swallow drugs or bowel obstruction, etc.) Unmitigated toxic reactions above Common Terminology Criteria for Adverse Events (CTCAE) grade 1 due to any prior treatment, excluding hair loss and peripheral sensory nerve disorders related to platinum-based chemotherapy; Received major surgical treatment, significant traumatic injury or long-term unhealed wounds or fractures (excluding needle biopsy for diagnosis, endoscope, etc.) within 28 days prior to the commencement of study treatment; With arterial/venous thrombotic events within 6 months, such as cerebrovascular accidents (including temporary ischemic attack, cerebral hemorrhage), deep venous thrombosis and pulmonary embolism; With active pulmonary tuberculosis, idiopathic pulmonary fibrosis, organized pneumonia, drug-induced pneumonia, radiation pneumonia requiring treatment or active pneumonia with clinical symptoms; History of psychotropic substance abuse and inability to quit or with mental disorders; Received allogeneic bone marrow transplantation or solid organ transplantation; Subjects with any severe and/or uncontrolled disease: i. Uncontrolled hypertension (defined as systolic BP >150 mm Hg or diastolic BP > 100 mm Hg pressure) ii. Grade 2 or greater cardiac ischemia, myocardial infarction or cardiac arrhythmia (including QTc ≥ 480 ms) ;and New York Heart Association (NYHA) Grade II or greater congestive heart failure; iii. Active or uncontrolled infections; iv. Decompensated liver cirrhosis and active hepatitis (Hepatitis B reference: HBsAg positive, and HBV DNA> 2500 copy/mL or > 500 IU/mL; Hepatitis C reference: HCV antibody positive, and HCV RNA > ULN); v. Renal failure requiring hemodialysis or peritoneal dialysis; vi. Known history of immunodeficiency infection; vii. Urinalysis:urine protein ≥ ++,and confirmed 24-hour urinary protein > 1.0g; 2 Tumor-related symptoms and treatment: History of surgery, chemotherapy, radiation or other anti-tumor therapy within 4 weeks prior to enrollment (calculated from the date of the last dose); History of Chinese patent drugs with anti-tumor indications approved by National Medical Products Administration (NMPA) (including compound cantharide capsule, Kangai injection, Kanglaite capsule/injection, Aidi injection, Brucea oil injection/capsule, Xiaoaoping tablet/injection, Huabenin capsule, etc.) within 2 weeks before enrollment; History of Tumor Immunotherapy of TGF-β inhibition; Previously received bevacizumab, arotinib, apatinib, renvatinib or other anti-vascular targeted drug therapy; History of secondary radiotherapy; Imaging (CT or MRI) evidence of tumor invading the significant blood vessels or likely to invade and cause fatal massive bleeding during study, accessed by investigators; With uncontrolled pleural effusion, pericardial effusion, or ascites that requires repeated drainage; Known uncontrolled or symptomatic active central nervous system (CNS) metastasis (characterized by clinical symptoms, brain edema, spinal cord compression, cancerous meningitis, leptomeningeal disease and /or progressive growth); (exclude those, with the history of CNS metastasis or spinal cord compression, clinical symptoms stabilized less than 4 weeks after discontinuation of dehydrants and steroids); 2 Research Treatment Related: History of live attenuated vaccine vaccination within 28 days prior to enrollment or planing of live attenuated vaccine vaccination during the study period; Definite bleeding tendency or bleeding symptoms with significant clinical significance within 28 days prior enrollment, including gastrointestinal bleeding, nasal bleeding (excluding epistaxis and retractive runny nose), and with hemorrhagic diseases or coagulation disorders; History of hemoptysis or hemoptysis within 28 days prior enrollment (defined as coughing or coughing out ≥ 1 teaspoon of blood or small blood clots or only coughing up blood without sputum) , blood in sputum are not excluded; Severe allergy history of antibody drugs or others; History of active autoimmune disease requiring systemic treatment within 2 years prior to enrollment (e.g. palliative drugs, corticosteroids, or immunosuppressants) . i. Including autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hypophysitis, vasculitis, nephritis, hyperthyroidism or multiple sclerosis; ii. Exclude Skin diseases without systemic treatment, such as vitiligo, psoriasis and hair loss; iii. Including asthma requiring medical intervention with bronchodilators; iv.Alternative therapy (such as thyroxine, insulin, or physiological corticosteroids for adrenal or pituitary insufficiency) is not considered as systemic therapy; Diagnosed with immunodeficiency or receiving systemic glucocorticoid therapy or any other form of immunosuppressive therapy. (dose of >10mg/ day prednisone or other equivalent efficacy hormone), and continued to use within 2 weeks prior to enrollment; 4 History of participating in other anti-tumor clinical trials in the previous 4 weeks; 5 Other damage to the safety of patients or other situations affecting patients to complete the study, assessed by investigators.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Li Zhang, Master
Phone
13902282893
Email
zhangli6@mail.sysu.edu.cn
Facility Information:
Facility Name
Affiliated Cancer Hospital and Institute of Guangzhou Medical University
City
Guangzhou
State/Province
Guangdong
ZIP/Postal Code
510000
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Weidong Li, Master
Phone
13725334110
Email
lwdlyn_hky@126.com
Facility Name
Sun-Yat-Sen University Cancer Center
City
Guangzhou
State/Province
Guangdong
ZIP/Postal Code
510060
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Li Zhang, Master
Phone
13902282893
Email
zhangli6@mail.sysu.edu.cn
Facility Name
Peking University Shenzhen Hospital
City
Shenzhen
State/Province
Guangdong
ZIP/Postal Code
518000
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Shubin Wang, Doctor
Phone
13823394076
Email
wangshubin2013@163.com
Facility Name
The Fifth Affiliated Hospital Sun Yat-Sen University
City
Zhuhai
State/Province
Guangdong
ZIP/Postal Code
519000
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Si Yang Wang, Bachelor
Phone
13570608929
Email
13570608929@163.com
Facility Name
Guangxi Tumor Hospital
City
Nanning
State/Province
Guangxi
ZIP/Postal Code
530021
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Song Qu, Doctor
Phone
13607887386
Email
daisyqs2002@163.com
Facility Name
Hainan General Hospital
City
Haikou
State/Province
Hainan
ZIP/Postal Code
570100
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Junmin Chen, Bachelor
Phone
18889808030
Email
18889808030@139.com
Facility Name
Hunan Cancer Hospital
City
Changsha
State/Province
Hunan
ZIP/Postal Code
410006
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yaqian Han, Master
Phone
18673176667
Email
hanyaqian@hnca.org.cn

12. IPD Sharing Statement

Learn more about this trial

To Evaluate the Safety and Efficacy of TQB2858 Injection to the Subjects With Recurrent/Metastatic Nasopharyngeal Cancer

We'll reach out to this number within 24 hrs